Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis

Rheumatology

Volumn 45, Issue 1, 2006, Pages 106-111

  Kapetanovic, Meliha C ^a   Saxne, T ^a   Sjoholm A ^b   Truedsson, L ^b   Jonsson G ^a   Geborek, P ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Antibody response; Methotrexate; Pneumococcal vaccination; Prednisolone; Rheumatoid arthritis; TNF blockers

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; METHOTREXATE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 29844450347     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei193     Document Type: Article

References (49)

1. Recommendations of the Swedish National Board of Health and Welfare. Pneumococcal Vaccination. (Socialstyrelsens allmänna råd). Vaccination motHpneumokocker. SOSFS 1994:26 (M). Available at: http://www.sos.se/sosfs/1994_26/1994_26.htm. Accessed 22 January 205.
2. CDC Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention of Pneumococcal Disease 1997/46 (RR-08);1-24. Available at: http://www.cdc.gov/mmwr/preview/mmwhtml/mm5241a3.htm. Accessed 22 January 2005.
3. Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: A meta-analysis. J Allergy Clin Immunol 1996;98:205-15.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infections in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
5. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
6. Mikuls TR. Co-morbidity in RA. Best Pract Res Clin Rheumatol 2003;17:729-52.
7. Segal BH, Sheller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic disease. Rheum Dis Clin North Am 1997;23:219-37.
8. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63.
9. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14.
10. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
11. Mohan AK, Cote TR, Siegel JN, Braun MM. Infectious complications of biologic treatment of rheumatoid arthritis. Curr Opin Rheumatol 2003;15:179-84.
12. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
13. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumour necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 22;46:2465-70.
14. Geborek P, Crnkic M, Petersson IF, Saxne T. South Swedish Treatment Group. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
15. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti TNF-alpha therapy. Rheumatology 2003;42:617-21.
16. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Cronh's disease. Inflamm Bowel Dis 2001;7:327.
17. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002;78:47-8.
18. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
19. Henriques Normark B, Kalin M, Örtqrist A et al. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J Infect Dis 2001;184:861-9.
20. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd edn. Philadelphia: W. B. Saunders, 1994:517-63.
21. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomised controlled trials. Arch Intern Med 1994;154:2666-77.
22. Cornu C, Yzébe D' Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immuno-competent adults: A meta-analysis of randomised trials. Vaccine 2001;19:4780-90.
23. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trial. BMC Fam Pract 2000;1:1.
24. Jackson LA, Neuzil KM, Yu O et al. for the Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747-54.
25. Örtqvist A, Hedlund J, Burman L-A et al. Swedish Pneumococcal Vaccination Study Group. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:339-403.
26. Dear K, Holden J, Andrews R, Tatham D. Vaccine for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003;(4):CD000422.
27. Hedlund J, Christenson B, Lundbergh P, Örtqvist Å. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: A 1-year follow-up. Vaccine 2003; 21:3906-11.
28. Simberkoff MS, Cross AP, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318-27.
29. Fry AM, Facklam RR, Whitny CG, Plikaytis BD, Schuchat A. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: Serotype and antimicrobial resistance patterns in the United States. J Infect Dis 2003;188:643-52.
30. Rubins JB, Alter MD, Loch J, Janoff EN. Determination of antibody responses of eldery adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999;67:5979-84.
31. O'Dell J, Gilg J, Palmer W, Haire C, Klassen L, Moore G. Pneumococcal vaccination: Decreased antibody response in rheumatoid arthritis patients on methotrexate. Arthritis Rheum 1992;9(Suppl.): 197.
32. O'Dell J, Gilg J, Palmer et al. Pneumococcal vaccine in rheumatoid arthritis. Decreased response while on methotrexate. J Clin Rheumatol 1996;2:59-63.
33. Elkayam O, Paran D, Caspi D et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34:147-53.
34. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumour necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.
35. Mease PJ, Ritchlin CT, Martin RW et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61.
36. Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology 2000;39:1159-61.
37. Van Riel PLCM, van Gestel AM, Scott DL on behalf of the EULAR standing committee for international clinical studies including therapeutic trials. The EULAR handbook of clinical assessment in rheumatoid arthritis. Alpen an den Rijn, The Netherlands: Van Zuiden Communications, 2000.
38. Van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van den Putte LBA, van Riel PLCM. Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with preliminary American College and the World Health Organization/International League against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
39. WHO. Training manual for enzyme linked immunosorbent assay for quantification of Streptococcus pneumoniae serotype specific IgG (PN PS ELISA). Available at: http://www.vaccine.uab.edu/2005_content/WHO9.pdf. Accessed 22 January 2005.
40. Quataert SA, Kirch CS, Wiedl LJ et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995;2:590-7.
41. Scheifele DW. Using vaccine responses to plumb the immunologic consequences of tumour necrosis factor blockade with etanercept. J Rheumatol 2004;31:1238-40.
42. Balmer P, North J, Baxter D et al. Measurement and interpretation of pneumococcal IgG levels for clinical management. Clin Exp Immunol 2003;133:364-9.
43. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
44. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:393-403.
45. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002;103:13-21.
46. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumour necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
47. De Rycke L, Kruithof E, van Damme N et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 2003;48:1015-23.
48. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72.
49. Shakoor N, Milchalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.